Skip to content

GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study

Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02686983
Acronym
DHC-GON-1
Enrollment
34
Registered
2016-02-22
Start date
2016-03-31
Completion date
2018-07-31
Last updated
2016-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine

Brief summary

Infiltration of the greater occipital nerve (GON) with local anaesthetics and corticosteroids is a treatment option for cluster headache. Corticosteroids may be helpful in reducing the pain intensity and frequency in chronic migrtaine. This RCT is set up to assess efficacy and safety of sub-occipital steroid injections with local anesthetic in patients with chronic migraine.

Detailed description

Infiltration of the greater occipital nerve (GON) with local anaesthetics and corticosteroids is a treatment option for cluster headache. In general, there is a marked paucity of evidence concerning GON blocks in migraine. Corticosteroids may be helpful in reducing the pain intensity and frequency in these patients. This is an RCT to assess efficacy and safety of sub-occipital steroid injections with local anesthetic in patients with chronic migraine.

Interventions

Infiltration of the greater occipital nerve .

Sponsors

Jakob Møller Hansen, MD.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Chronic migraine

Exclusion criteria

* Medication overuse headache

Design outcomes

Primary

MeasureTime frameDescription
Number of migraine days8 weeksNumber of days fulfilling the ICHD criteria for migraine

Secondary

MeasureTime frameDescription
Number of days with severe headache days8 weeksNumber of days with severe headache days
Medication use8 weeksuse of medication recorded during the 8 weeks
Responder rate8 weeksnumber of patients with more than 50% reduction in migraine
Number of migraine attacks8 weeksNumber of attacks fulfilling the ICHD criteria for migraine

Countries

Denmark

Contacts

Primary ContactJakob Møller Hansen
jamoha01@regionh.dk

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026